Comments
Loading...

Maravai LifeSciences Analyst Ratings

MRVINASDAQ
Logo brought to you by Benzinga Data
$2.28
At close: Jun 11 EDT
$2.35
0.073.02%
Pre-Market: 6:53 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$35.00
Lowest Price Target1
$2.00
Consensus Price Target1
$10.65

Maravai LifeSciences Analyst Ratings and Price Targets | NASDAQ:MRVI | Benzinga

Maravai LifeSciences Holdings Inc has a consensus price target of $10.65 based on the ratings of 15 analysts. The high is $35 issued by Goldman Sachs on July 14, 2022. The low is $2 issued by Baird on May 13, 2025. The 3 most-recent analyst ratings were released by Craig-Hallum, Baird, and Morgan Stanley on May 13, 2025, May 13, 2025, and March 25, 2025, respectively. With an average price target of $5.67 between Craig-Hallum, Baird, and Morgan Stanley, there's an implied 141.25% upside for Maravai LifeSciences Holdings Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Feb
1
2
Mar
1
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Craig-Hallum
Baird
Morgan Stanley
UBS
B of A Securities

1calculated from analyst ratings

Analyst Ratings for Maravai LifeSciences

Buy NowGet Alert
05/13/2025Buy Now325.73%Craig-Hallum
Christian Schwab74%
$12 → $10MaintainsBuyGet Alert
05/13/2025Buy Now-14.85%Baird
Catherine Schulte66%
$3 → $2MaintainsNeutralGet Alert
03/25/2025Buy Now112.87%Morgan Stanley
Tejas Savant50%
$7 → $5MaintainsEqual-WeightGet Alert
03/21/2025Buy Now6.43%UBS
Dan Brennan63%
$8 → $2.5MaintainsNeutralGet Alert
03/03/2025Buy Now240.58%B of A Securities
Michael Ryskin46%
$9 → $8MaintainsBuyGet Alert
02/26/2025Buy Now27.72%Baird
Catherine Schulte66%
$9 → $3DowngradeOutperform → NeutralGet Alert
12/05/2024Buy Now80.94%Goldman Sachs
Matthew Sykes64%
$7 → $4.25DowngradeNeutral → SellGet Alert
11/14/2024Buy Now—Wolfe Research
Doug Schenkel72%
—Initiates → Peer PerformGet Alert
11/08/2024Buy Now453.45%RBC Capital
Conor McNamara36%
$17 → $13MaintainsOutperformGet Alert
11/08/2024Buy Now—William Blair
Matt Larew25%
—DowngradeOutperform → Market PerformGet Alert
11/08/2024Buy Now283.16%Baird
Catherine Schulte66%
$10 → $9MaintainsOutperformGet Alert
10/08/2024Buy Now198.01%Goldman Sachs
Matthew Sykes64%
$8 → $7MaintainsNeutralGet Alert
08/27/2024Buy Now325.73%Wells Fargo
Brandon Couillard68%
→ $10Initiates → OverweightGet Alert
08/16/2024Buy Now538.6%RBC Capital
Conor McNamara36%
$15 → $15ReiteratesOutperform → OutperformGet Alert
08/13/2024Buy Now325.73%Morgan Stanley
Tejas Savant50%
$11 → $10DowngradeOverweight → Equal-WeightGet Alert
08/08/2024Buy Now240.58%Goldman Sachs
Matthew Sykes64%
$7 → $8MaintainsNeutralGet Alert
08/08/2024Buy Now368.3%UBS
Dan Brennan63%
$8.5 → $11MaintainsNeutralGet Alert
07/09/2024Buy Now198.01%Goldman Sachs
Matthew Sykes64%
$8 → $7MaintainsNeutralGet Alert
05/09/2024Buy Now325.73%Baird
Catherine Schulte66%
$8 → $10MaintainsOutperformGet Alert
04/10/2024Buy Now538.6%Craig-Hallum
Christian Schwab74%
→ $15Initiates → BuyGet Alert
02/23/2024Buy Now496.02%RBC Capital
Conor McNamara36%
$12 → $14MaintainsOutperformGet Alert
02/23/2024Buy Now325.73%Stifel
Daniel Arias78%
$11 → $10MaintainsBuyGet Alert
12/12/2023Buy Now240.58%B of A Securities
Michael Ryskin46%
$10 → $8UpgradeNeutral → BuyGet Alert
11/09/2023Buy Now198.01%Goldman Sachs
Matthew Sykes64%
$8 → $7MaintainsNeutralGet Alert
11/09/2023Buy Now368.3%Morgan Stanley
Tejas Savant50%
$12 → $11MaintainsOverweightGet Alert
08/09/2023Buy Now410.88%Morgan Stanley
Tejas Savant50%
$27 → $12MaintainsOverweightGet Alert
08/08/2023Buy Now623.74%Deutsche Bank
Justin Bowers46%
$23 → $17MaintainsBuyGet Alert
08/08/2023Buy Now666.32%RBC Capital
Conor McNamara36%
$20 → $18MaintainsOutperformGet Alert
08/08/2023Buy Now240.58%Goldman Sachs
Matthew Sykes64%
$12 → $8MaintainsNeutralGet Alert
08/08/2023Buy Now368.3%Baird
Catherine Schulte66%
$18 → $11MaintainsOutperformGet Alert
08/08/2023Buy Now368.3%Credit Suisse
Dan Leonard55%
$14 → $11MaintainsNeutralGet Alert
08/08/2023Buy Now—Keybanc
Paul Knight54%
—DowngradeOverweight → Sector WeightGet Alert
05/23/2023Buy Now496.02%Credit Suisse
Dan Leonard55%
$18 → $14DowngradeOutperform → NeutralGet Alert
05/10/2023Buy Now453.45%Goldman Sachs
Matthew Sykes64%
$16 → $13MaintainsNeutralGet Alert
05/10/2023Buy Now1049.47%Morgan Stanley
Tejas Savant50%
$29 → $27MaintainsOverweightGet Alert
05/09/2023Buy Now751.46%RBC Capital
Conor McNamara36%
$22 → $20MaintainsOutperformGet Alert
05/09/2023Buy Now453.45%Goldman Sachs
Matthew Sykes64%
$16 → $13DowngradeBuy → NeutralGet Alert
05/09/2023Buy Now879.18%Deutsche Bank
Justin Bowers46%
$25 → $23MaintainsBuyGet Alert
05/09/2023Buy Now666.32%Credit Suisse
Dan Leonard55%
$23 → $18MaintainsOutperformGet Alert
02/24/2023Buy Now1134.62%Morgan Stanley
Tejas Savant50%
$32 → $29MaintainsOverweightGet Alert
02/23/2023Buy Now836.61%Baird
Catherine Schulte66%
$25 → $22MaintainsOutperformGet Alert
02/23/2023Buy Now879.18%Credit Suisse
Dan Leonard55%
$26 → $23MaintainsOutperformGet Alert
02/23/2023Buy Now921.75%Keybanc
Paul Knight54%
$28 → $24MaintainsOverweightGet Alert
01/17/2023Buy Now581.17%Goldman Sachs
Matthew Sykes64%
$18 → $16MaintainsBuyGet Alert
01/05/2023Buy Now581.17%UBS
Dan Brennan63%
$20 → $16DowngradeBuy → NeutralGet Alert
12/14/2022Buy Now964.33%Deutsche Bank
Justin Bowers46%
→ $25Initiates → BuyGet Alert
12/07/2022Buy Now836.61%RBC Capital
Conor McNamara36%
→ $22Initiates → OutperformGet Alert
11/04/2022Buy Now666.32%Goldman Sachs
Matthew Sykes64%
$30 → $18MaintainsBuyGet Alert
11/04/2022Buy Now1262.34%Morgan Stanley
Tejas Savant50%
$35 → $32MaintainsOverweightGet Alert
11/03/2022Buy Now623.74%B of A Securities
Michael Ryskin46%
$32 → $17DowngradeBuy → NeutralGet Alert
11/03/2022Buy Now1006.9%Credit Suisse
Dan Leonard55%
$34 → $26MaintainsOutperformGet Alert
11/03/2022Buy Now1092.05%Keybanc
Paul Knight54%
$35 → $28MaintainsOverweightGet Alert
08/25/2022Buy Now1347.49%Credit Suisse
Dan Leonard55%
→ $34Initiates → OutperformGet Alert
08/08/2022Buy Now1390.06%Morgan Stanley
Tejas Savant50%
$49 → $35MaintainsOverweightGet Alert
07/14/2022Buy Now1390.06%Goldman Sachs—$44 → $35MaintainsBuyGet Alert

FAQ

Q

What is the target price for Maravai LifeSciences (MRVI) stock?

A

The latest price target for Maravai LifeSciences (NASDAQ:MRVI) was reported by Craig-Hallum on May 13, 2025. The analyst firm set a price target for $10.00 expecting MRVI to rise to within 12 months (a possible 325.73% upside). 18 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Maravai LifeSciences (MRVI)?

A

The latest analyst rating for Maravai LifeSciences (NASDAQ:MRVI) was provided by Craig-Hallum, and Maravai LifeSciences maintained their buy rating.

Q

When was the last upgrade for Maravai LifeSciences (MRVI)?

A

The last upgrade for Maravai LifeSciences Holdings Inc happened on December 12, 2023 when B of A Securities raised their price target to $8. B of A Securities previously had a neutral for Maravai LifeSciences Holdings Inc.

Q

When was the last downgrade for Maravai LifeSciences (MRVI)?

A

The last downgrade for Maravai LifeSciences Holdings Inc happened on February 26, 2025 when Baird changed their price target from $9 to $3 for Maravai LifeSciences Holdings Inc.

Q

When is the next analyst rating going to be posted or updated for Maravai LifeSciences (MRVI)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Maravai LifeSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Maravai LifeSciences was filed on May 13, 2025 so you should expect the next rating to be made available sometime around May 13, 2026.

Q

Is the Analyst Rating Maravai LifeSciences (MRVI) correct?

A

While ratings are subjective and will change, the latest Maravai LifeSciences (MRVI) rating was a maintained with a price target of $12.00 to $10.00. The current price Maravai LifeSciences (MRVI) is trading at is $2.35, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch